We tested the hypothesis that changes in the phenotype of CD8 1 T cells from patients with chronic graftversus-host disease (cGVHD) correlate with disease activity, and resolve or normalize in clinically tolerant patients successfully withdrawn from immunosuppression therapy (IST). No significant difference was found in the absolute CD8 1 T cell counts among cGVHD patients, tolerant patients, and healthy controls. However, compared with healthy normal controls, CD8 1 T cells from cGVHD patients had decreased expression of the IL-7 receptor and an increase in effector T cells, Ki-67, and perforin expression and apoptosis, suggesting that activation, differentiation, and proliferation of host-reactive CD8 1 effector T cells is a mechanism by which cGVHD is sustained and persists. The increase in effector T cells was most prominent in older patients and patients who were cytomegalovirus seropositive before transplantation. Use of IST was associated with a decreased number of CD45RA 2 CD8 1 effector T cells, a decreased expression of Ki-67, and an increased expression of CD95 (Fas). Together, these results demonstrate that CD8 1 T cells in patients with cGVHD are characterized by an increased level of activation and proliferation, and an expansion of effector cells that appear to be selectively sensitive to IST compared with other CD8 1 T cells. In GVHD-free tolerant patients, CD8 1 T cells showed an increased expression of granzyme and HLA-DR molecules compared with CD8 1 T cells from healthy controls, indicating that clinical tolerance in these patients can occur without full normalization of the CD8 1 T cell phenotype.
INTRODUCTION
Chronic graft-versus-host disease (cGVHD) is a frequent complication of allogeneic hematopoietic cell transplantation (HCT), affecting 40% to 60% of patients with onset occurring within 6 to 24 months post-HCT [1] . Chronic GVHD is more likely to occur in patients who have previously had acute GVHD (aGVHD), but not all patients with resolved aGVHD develop cGVHD. Chronic GVHD can also develop in the absence of prior aGVHD [2] [3] [4] . Duration of cGVHD is variable and on average requires systemic immunosuppression therapy (IST) for a median of 24 to 36 months [5] . Absence of aGVHD or cGVHD activ-ity after withdrawal of IST has been interpreted as indicating the development of clinical immunologic tolerance [1, 2, 5, 6] . It is unknown, however, whether ''clinical tolerance'' following HCT meets the classical experimental definition of immunologic tolerance. The mechanism by which cGVHD evolves into quiescence characterized by lack of clinical signs and symptoms without need for immune suppressive medications is also unknown.
Donor T cells are recognized as the primary mediators of aGVHD, but less is known about the role of T cells in cGVHD. It is commonly assumed that cGVHD is mediated and sustained by donor T cells reactive to host-specific alloantigen, although immune dysfunction and autoreactivity may also contribute to the pathologic lesions characteristic of cGVHD [7, 8] . Two previous studies have examined CD8 1 T cells in patients with cGVHD. Yamashita et al. [9] reported a significant increase in CD45RA 2 CCR7 1 central memory T cells, and D'Asaro et al. [10] showed an increase in CD45RA 1 CCR7 2 effector T cells in patients with cGVHD. In the study reported here, we performed a cross-sectional study of patients returning at various times posttransplantation for assessment and management of cGVHD. Research blood samples were obtained and examined for the relative numbers of na€ ıve (T N ), central memory (T CM ), effector memory (T EM ), and effector (T EFF ) CD8 1 T cell subsets as well as T cell effector molecules and activation markers to test the hypotheses (1) that changes in CD8 1 T cell phenotype in cGVHD patients correlates with disease activity, (2) that these changes resolve or normalize in clinically tolerant patients who have been successfully withdrawn from IST without recurrence of GVHD, and (3) that IST use is associated with specific CD8 phenotypes in patients with cGVHD. Our major findings include an increase in CD8 1 T EFF cells overall, an increased expression of perforin and Ki-67, and a decrease in T N cells in patients with cGVHD, along with a decrease in CD45RA 2 T EFF cells during IST. T EFF levels, and perforin and Ki-67 expression were normal in tolerant patients; however, tolerant patients also showed an unexpected increase in the expression of HLA-DR and granzyme A. These results overall provide a framework for future functional studies aimed at defining the mechanism(s) by which clinical tolerance occurs following HCT.
METHODS

Study Population and Samples
The study population included 273 patients who had a comprehensive history and physical examination for the presence or absence of cGVHD at our Long-Term Follow-Up Clinic. All patients received T cell replete bone marrow (n 5 53), mobilized peripheral blood cells (n 5 218), or umbilical cord blood (n 5 2), from a related (n 5 146) or unrelated (n 5 127) donor, for the treatment of a hematologic malignancy or myelodysplasia. Cyclosporine or tacrolimus, and short methotrexate or mycophenolate mofetil, were given for aGVHD prophylaxis. Heparinized blood was obtained from patients at a median of 28 months post-HCT (range: 6-271 months), and from healthy normal volunteers who had no history of HCT (''controls''). The median age of the patients at the time of transplantation was 46 years (range: , and the median age of their donors was 38 years (range: 0-76). The median age of healthy normal controls was 37 years (range: . Peripheral blood mononuclear cells were isolated by Ficoll-Hypaque density centrifugation, washed, and aliquoted for cryopreservation in 10% DMSO and 90% fetal bovine serum, and were later thawed for cell surface and intracellular staining. All participants gave informed consent according to institutional review board approved protocols.
Classification of cGVHD
Graft-versus-host disease (GVHD) status was evaluated at the time that blood samples were obtained. A diagnosis of clinical cGVHD was established according to the recommendations of the National Institutes of Health Consensus Conference [11, 12] . Clinical tolerance was defined as the absence of all reversible signs and symptoms of GVHD in patients withdrawn from all IST for at least 3 months at the time of blood collection and with 6 months of additional follow-up without recurrence of cGVHD. Patients were classified for evidence of disease activity and use of IST and assigned to 1 of 4 categories as illustrated in Figure 1 . Patients with ''controlled'' or quiescent cGVHD who were still on IST were excluded from the study. The remaining patients were classified into 3 groups as follows: (1) cGVHD, receiving IST; (2) cGVHD without IST; and (3) tolerant, either with no history of cGVHD or after recovery from cGVHD.
Cell Surface and Annexin Staining
Thawed peripheral blood mononuclear cells were examined by flow cytometry after staining with a series of fluorochrome-labeled antihuman monoclonal antibodies for cell-surface molecules. Cells subjected to 3-color staining were analyzed on a BD FACScan and cells stained for .3 colors were analyzed on a BD LSRII. The collected data were further analyzed with the use of BD CellQuest Pro software. Reagents included CD8 FITC, CD95 (FAS) FITC, CD127 (IL-7Ra) PE, CD8 PE-Cy5, HLA-DR PerCP-Cy5.5, CD279 (PD-1) APC, and CD3 APC-Cy7 (BD Pharmingen, San Diego, CA), CD62L PerCP-Cy5.5, CD45RA Pacific Blue, and CD62L Alexa Fluor 700 (Biolegend, San Deigo, CA). Isotype-matched negative control antibodies included IgG1k FITC, IgG1k PE, IgG2ak PerCP-Cy5.5, IgG1k APC, IgG1k APC-Cy7, and IgG1k Alexa Fluor 700 isotype antibodies (BD Pharmingen), and with IgG1k PerCP-Cy5.5, IgG1k PE-Cy7, IgG2bk APC, and IgG2bk Pacific Blue (Biolegend). Apoptosis was assessed by staining thawed cells with Annexin V FITC (Apoptosis Detection Kit I, BD Pharmingen) at 24 hours after in vitro culture in RPMI 1640 (Gibco, Gaithersburg, MD) with 10% fetal bovine serum (Invitrogen, Carlsbad, CA) in a CO 2 incubator at 37 C.
Intracellular Staining
Staining of CD8 1 T cell subsets for cytoplasmic proteins was accomplished in a 2-step process. First, cell-surface staining was performed, then cells were fixed and permeabilized for intracellular staining with the BD Pharmingen Cytofix/Cytoperm fixation/ permeabilization reagents and protocol according to the manufacturer's instructions, and stained with the following antibodies: FITC-conjugated Ki-67 (BD Pharmingen); PerCP-Cy5.5-conjugated Granzyme A and APC-conjugated Perforin (Biolegend).
Definition of CD8 1 T Cells
Two populations of CD8 1 T cells can be identified according to the expression level of CD8 as CD8 bright and CD8 dim . Approximately 80% of the CD8 1 population stained CD8 bright in both patients and normal controls (data not shown). The composition of the CD8 dim and CD8 bright subsets were examined in detail in 46 patients and 9 controls by staining for CD3, CD56, and CD4. The majority of the CD8 dim cells in both patients and controls were CD56 1 (62.0% 6 2.5% and 64.8% 6 3.3%, P 5 .50), and \25% were CD3 1 CD4 2 CD56 2 (22.5% 6 1.7% and 23.8% 6 4.2%, respectively), indicating that the CD8 dim population consisted mostly of natural killer or natural killer T cells. In contrast, 87.4% 6 1.1% of patient and 88.3% 6 2.2% of control CD8 bright cells were CD3 1 CD4 2 CD56 2 . Based on these findings, we restricted our study to the CD8 bright lymphocyte population, thus excluding from the subsequent analysis natural killer and natural killer T cells [13, 14] .
Definition of CD8 1 T Cell Subsets
CD8 subsets were characterized according to expression of CD62L and CD127 as previously described by Bachmann et al. [19] and Huster et al. [20] . Staining with CD45RA was included to help distinguish na€ ıve and central memory CD8 1 T cells, and to serve as a marker for identifying the CD45RA 2 and CD45RA 1 CD8 1 T EFF subsets. CD8 1 T cells were gated to define subsets in the following fashion: na€ ıve (T N ), CD62L 1 CD127 1 CD45RA 1 ; central memory (T CM ), CD62L 1 CD127 1 CD45RA 2 ; and effector memory (T EM ), CD62L 2 CD127 1 CD45RA 2 . CD8 1 effector (T EFF ) T cells were defined as CD62L 2 CD127 2 . CD45RA expression was used to further subdivide T EFF into RA 1 and RA 2 subsets (illustrated in Figure 2 ).
Statistical Analysis
Multivariate regression analysis was used to compare T cell counts among patients who had cGVHD without IST, cGVHD during IST, tolerant patients, and healthy normal controls, adjusting for age of patients and controls. Clinical variables that might affect the observed T cell counts and phenotype including hematopoietic cell source (marrow, peripheral blood), donor relationship (related, unrelated), age of patient at the time of HCT and at the time of study, cytomegalovirus (CMV) serostatus of the patient before HCT, sex mismatch (female donor for a male recipient, other), cGVHD status at the time of study (presence, absence), use of IST (yes, no), history of aGVHD (yes, no), history of cGVHD (yes, no), and time from transplantation were examined in a multivariate regression model (results of the multivariate analysis are summarized in Supplemental Tables S1-S3) . P values were calculated using a 2-tailed t test and were adjusted for age at the time of sample collection when comparing patients and normal controls. Donor age was also examined but had no significant effect on the numbers or phenotypes of T cells after HCT (data not shown). Pearson correlation coefficients were calculated to evaluate the relationship between age and T cell counts in patients and controls. All P values are 2 sided and are not adjusted for multiple comparisons. P values #.01 were considered statistically significant, whereas P values between ..01 and #.05 were considered marginally significant.
RESULTS
T Cell Counts in cGVHD and Tolerant Patients
The absolute number of CD3 1 and CD8 1 T cells were comparable in cGVHD patients, tolerant patients, and normal controls, but the absolute number of CD4 1 T cells was significantly decreased in patients with cGVHD (660 6 35 cells/mL; P 5 .009), especially during IST (635 6 44 cells/mL, P 5 .006) compared with controls (856 6 47 cells/mL) ( Table 1 ). The absolute CD3 1 and CD4 1 T cell counts were greater with increasing time post-HCT, and higher absolute CD3 1 , CD4 1 , and CD8 1 T cell counts were observed in CMV-seropositive patients (P \ .001, P 5 .03, and P\.001, respectively). We found no statistically significant effect of patient or donor age, donor type, or use of IST on the numbers of CD3 1 or CD8 1 T cells in patients with cGVHD or in tolerant patients (Table S1 ).
Expression of CD127
CD127, the IL-7 receptor, is essential for the survival of memory T cells, and its expression can be used to define T cell subsets with distinct functional properties [17] . We observed a significant decrease in the expression of CD127 on CD8 1 T cells from patients with cGVHD compared with normal controls (48% 6 3% versus 72% 6 3%, P \ .001) ( Figure 3 ). CD127 expression tended to normalize in tolerant patients compared with normal controls (62% 6 4% versus 72% 6 3%, P 5 ns). In the multivariate regression model, the percentage of CD8 1 T cells expressing CD127 was lower in older patients (20.7%/year; P\.001) and patients who were CMV seropositive before HCT (213.5%, P 5 .01) (Table S2A ), but was not associated with donor age (data not shown).
Analysis of CD8 1 T Cell Subsets
The percentage of CD8 1 T EFF cells was significantly increased in patients with cGVHD overall compared with normal controls (39% 6 3% versus 19% 6 3%, P \ .001) (Table 2A ). There was also a 3-fold increase in the absolute number of T EFF in cGVHD patients overall compared with normal controls (158 6 32 versus 54 6 14 cells/mL); however, this difference was only of marginal significance when adjusted for age (P 5 .05) (Table 2B ). IST had no significant effect on either the percentage (38% 6 4% during IST versus 40% 6 4% without IST, P 5 ns) (Table 2A) or the absolute number of T EFF in GVHD patients (144 6 50 cells/mL during IST versus 171 6 41 cells/mL without IST, P 5 ns) ( Table 2B ). The observed increase in T EFF in patients with cGVHD was balanced by a significant decrease in the percentage and absolute number of T N compared with controls (20% 6 2% versus 35% 6 4%, P 5 .001; and 34 6 5 cells/mL versus 84 6 25 cells/mL, P 5 .003, respectively). Although there was a significant decrease in the percentage of T EM in cGVHD patients overall compared with controls (13% 6 1% versus 19% 6 2%, P 5 .004), there was no significant difference in the absolute number of T EM in cGVHD patients overall compared with controls (43 6 9 cells/mL versus 46 6 11 cells/mL, P 5 ns). There was also no significant difference in the percentage or absolute number of T CM cells in cGVHD patients compared with controls (Table 2A-B) .
In tolerant patients, neither the percentage nor the absolute number of T EFF were significantly different from normal controls (27% 6 4% versus 19% 6 3%, Figure 2 . Staining of CD8 subsets. Thawed peripheral blood mononuclear cells were stained with CD82FITC, CD45RA2Pacific Blue, CD127-PE, and CD62L-PerCP-Cy5.5 antibodies and PBL were gated using CellQuest Pro. (A) Subsequent gating was performed on CD8 bright CD45RA 2 (gate R2) and CD8 bright CD45RA 1 (gate R3) cells. (B) The CD45RA 2 population (gate R2) was further divided into quadrants based on CD127 and CD62L expression to define the following populations: CD127 1 CD62L 2 T EM (UL), CD127 1 CD62L 1 T CM (UR), and CD127 2 CD62L 2 RA 2 T EFF (LL). (C) The CD8 1 CD45RA 1 population (gate R3) was divided in a similar fashion to define the CD127 1 CD62L 1 T N (UR) and CD127 2 CD62L 2 RA 1 T EFF (LL) populations. The same healthy control and chronic GVHD patients, who were off IST, were used for illustration in each panel. Percentages displayed represent percent of CD8 bright CD45RA 2 (R2) or percent of CD8 bright CD45RA 1 (R3). P 5 ns; and 54 6 12 cells/mL versus 54 6 14 cells/mL, P 5 ns, respectively). There was also no significant difference in the absolute number of T N in tolerant patient compared with controls (63 6 16 versus 84 6 25 cells/mL, P 5 ns), but there was a trend of marginal significance for a decrease in the percentage of T N in tolerant patients compared with controls (25 6 4% versus 35% 6 4%, P 5 .05). There was no significant difference in the percentage and absolute number of T CM and T EM in tolerant patients compared with normal controls (Table 2A -B and Figure 4A -B).
Taken together, the changes in the percentage and absolute numbers of T EFF and T N demonstrate a marked increase of T EFF in cGVHD patients coupled with a decline in both the percentage and absolute number of T N , and a decline in the relative percentage of T EM , whereas no significant changes were seen in the percentage or absolute number of T CM cells. These results overall suggest an expansion of T EFF cells by proliferation and/or increased survival, and a decrease in the production or an increase in the recruitment and activation of T N in cGVHD patients, changes that tended to normalize in tolerant patients.
Additional changes were seen in the T EFF subsets in cGVHD patients, especially during IST. The percentage and absolute number of RA 2 T EFF cells were increased in cGVHD patients overall compared with normal controls (15% 6 2% versus 7% 6 1%, P 5 .006; and 67 6 15 versus 18 6 5 cells/mL, P 5 .05). This increase was especially prominent in cGVHD patients without IST (20% 6 2%, P \ .001; and 88 6 23 cells/mL, P 5 .01). The percentage of RA 2 T EFF cells was lower in cGVHD patients during IST (10% 6 2% during IST versus 20% 6 2% without IST, P 5 .009), and there was a lower absolute number of RA 2 T EFF cells (43 6 17 cells/mL during IST versus 88 6 23 cells/mL without IST), but this apparent difference was not statistically significant. The percentage and absolute number of RA 2 T EFF cells in patients during IST were not significantly different from controls (Table 2A -B and Figure 4A -B). The percentage of RA 1 T EFF was increased in cGVHD patients overall compared with controls (24% 6 2% versus 12% 6 2%, P 5 .002) together with a trend for an increase in the absolute number of RA 1 T EFF cells (92 6 19 versus 37 6 10 cells/mL, P 5 .07). These increases in percentage and absolute number of RA 1 T EFF were more prominent in cGVHD patients during IST (28% 6 3%, P \ .001 and 101 6 33 cells/mL, P 5 .06) than in cGVHD patients without IST (21% 6 3%, P 5 .05 and 83 6 20 cells/mL, P 5 .16), whereas the opposite was observed in RA 2 T EFF cells indicating that the latter are IST sensitive. In tolerant patients, the percentage of RA 2 T EFF remained marginally increased compared with normal controls (13% 6 2% versus 7% 6 1%, P 5 .05), whereas the percentage of RA 1 T EFF was essentially the same as in normal controls (13% 6 2% versus 12% 6 2%, P 5 ns). There was no significant difference in the absolute number of RA 1 or RA 2 T EFF cells in tolerant (Table 2B and Figure 4B ).
In a multivariate regression model, the percentages of T N and overall T EFF (both RA 2 T EFF and RA 1 T EFF ), but not T CM or T EM, were associated with patient age. The percentage of T N was lower in older individuals (20.7%/year, P \ .001), whereas the percentage of RA 2 and RA 1 T EFF was higher in older individuals (10.2%/y, P 5 .02; and 10.4%/year, P \ .001, respectively). The percentage of T N was lower in CMV seropositive patients (28.1%, P 5 .03), whereas the percentage of RA 2 and RA 1 T EFF was higher in CMV seropositive patients (17.2%, P 5 .01; and 17.1%, P 5 .04, respectively). The percent-age of T CM , but not T EM , was lower in CMV seropositive patients (25.0%/year, P 5 .007) (Table S2A and Figure 5 ). The multivariate analysis also confirmed a decrease in absolute T N counts associated with age (20.14 cells/mL/year, P 5 .005), and an increase in T EFF cells associated with age (10.40 cells/mL/year, P 5 .04) (Table S2B ). Additionally, the multivariate analysis showed an increase in the percentage T EFF and absolute T EFF cell counts (P 5 .005 and P 5 .001, respectively) and revealed an increase in the absolute T EM cell counts in CMV seropositive patients (P 5 .004). The association between use of IST and a lower percentage of RA 2 T EFF in cGVHD patients also remained significant in the multivariate regression analysis (P 5 .009) (Table S2A ). GVHD indicates graft-versus-host disease; IST, immunosuppression therapy. *Data consist of absolute cell counts (cells/mL) expressed as the mean 6 SEM (P values). All P values represent comparisons between patients and normal controls and are adjusted for age of patients and normal controls. Adjusted P values >.05 are omitted. †The chronic GVHD without IST group consists of 18 patients with ''mild'' and 4 patients with ''moderate/severe'' disease. Both subgroups showed similar trends in CD8 + T cell subsets, including an increase in the absolute number of T EFF in both mild and moderate/severe GVHD patients (170 6 48 and 175 6 71 cells/mL), and a decrease in T N in both mild and moderate/severe GVHD patients (36 6 9 and 40 6 16 cells/mL).
‡The ''other'' category includes 3 additional CD8 + T cell subsets (CD45RA 2 CD127 2 CD62L + , CD45RA + CD127 2 CD62L + , and CD45RA + CD127 + CD62L 2 ).
Activation Markers (HLA-DR, CD95, and PD-1)
The percentage of HLA-DR 1 cells in the CD8 1 population was not increased in patients with cGVHD but was increased in tolerant patients compared with controls (9% 6 3% versus 4% 6 1%, P 5 .002) ( Table 3 ). The percentage of HLA-DR 1 cells was lower in older patients (20.22%/year, P 5 .01), but increased with time from HCT (11.29%/year, P\.001) ( Table S3 ). The percentage of CD8 1 cells expressing CD95 (Fas) was significantly increased in patients with cGVHD during IST compared with controls (59% 6 3% versus 40% 6 3%; P 5 .005), and in patients during IST compared with those without IST (59% 6 3% versus 47% 6 4%, P 5 .008) ( Tables 3  and S3 ). The percentage of CD95 1 cells was also found to increase with age (10.5%/year, P 5 .005) (Table S3 ). CD95 expression was variable among the CD8 1 T subsets. In normal controls, CD95 expression was lowest in T N cells (20% 6 2%), highest in T CM (75% 6 3%), and was higher in RA 2 compared with RA 1 T EFF cells (64% 6 4% versus 32% 6 5%, P \ .001). Similar parallel differences in CD95 expression were observed among T N , T CM , and RA 1 and RA 2 T EFF cells in cGVHD and tolerant patients (data not shown). We found no statistically significant difference in the expression of PD-1, a member of the CD28/CTLA-4 family of T cell regulators, in tolerant patients, or cGVHD patients either during or without IST compared with normal controls. A history of aGVHD, however, was associated with a lower percentage of cells expressing PD-1 (218.3%, P 5 .008) (Table S3 ). Among CD8 1 T cell subsets, PD-1 expression in patients was lowest in T EM cells and highest in RA 2 T EFF cells (28% 6 4% and 45% 6 4%), both similar to normal controls (T EM cells, 37% 6 6%; and RA 2 T EFF cells, 52% 6 5%).
Perforin and Granzyme A Expression
We observed a significant increased percentage of CD8 1 cells expressing perforin in cGVHD patients overall (46% 6 4%), but not in tolerant patients (29% 6 5%), compared with controls (21% 6 5%) (P 5 .003 and P 5 ns, respectively) ( Table 3) . Perforin levels were also higher in CMV seropositive patients (124.2%, P \ .001). In contrast, the percentage of CD8 1 cells expressing granzyme A was increased in tolerant patients compared with controls (27% 6 5% versus 11% 6 4%, P 5 .004), but not in patients with cGVHD (16% 6 3%, P 5 ns). Patient age, time from HCT, and CMV serostatus had no significant effect on granzyme expression (Table S3 ).
Proliferation and Apoptosis
The percentage of CD8 1 T cells expressing Ki-67, a marker for recent proliferation, was increased in patients with cGVHD compared with controls (5% 6 1% versus 3% 6 0.5%, P 5 .04), especially in patients who had cGVHD without IST (6% 6 2%, P 5 .01) (Table 3) . Similarly, we found a statistically significant increase in the percentage of apoptotic CD8 1 T cells in patients with cGVHD compared with normal controls (50% 6 5% versus 31% 6 4%, P 5 .01) ( Table  3 ). The percentages of Ki-67 1 and apoptotic cells in the CD8 1 T population of tolerant patients were not significantly different from controls. In cGVHD patients, Ki-67 expression was shown to be significantly increased in CD8 1 T CM cells during and without IST (P 5 .01 and P 5 .007, respectively), and in T EM cells in cGVHD patients without IST compared with normal controls (Figure 6 ). There was also an increased percentage of Ki-67 1 cells in T N cells in cGVHD patients during IST (2.5% 6 0.5%, P 5 .008), and in tolerant patients (2.0% 6 0.4%, P 5 .03) compared with normal controls (0.4% 6 0.1%). The highest Ki-67 1 expression levels were seen among T EFF cells, especially among RA 2 T EFF cells in cGVHD patients without IST. During IST, Ki-67 expression was significantly suppressed in RA 1 T EFF cells (6% 6 1% versus 2% 6 0.3%, P 5 .02 and in the RA 2 T EFF cells (15% 6 4% versus 5% 6 1%, P 5 .05). These IST-associated effects are consistent with the hypothesis that activation, proliferation, and/or survival of T EFF cells in cGVHD patients is inhibited by the administration of IST.
DISCUSSION
This study population represents a large crosssectional cohort of patients from 1 year to 23 years (median: 28 months) after HCT who were seen for evaluation and management in our Long-term Follow-Up Clinic. All patients received a systematic and standard assessment for the presence of cGVHD according to the guidelines of the recent NIH Consensus Conference [11] . The patient category ''cGVHD without IST'' included patients with both mild and moderate/severe disease; however, similar trends in CD8 subsets, activation markers, and effector phenotype were observed in both groups. Patients with no clinical manifestations of cGVHD while still on IST were excluded from the study.
The major finding in this study was an increase in the percentage and absolute number of CD8 1 T EFF cells. The increased expression of perforin, Ki-67, and annexin that we observed in patients with cGVHD compared with healthy controls suggests that mature effector T cells are not only expanded in these patients, but that they are also maintained in a state of activation that persists for several months or years after transplantation. Ki-67 expression levels were increased not only in T EFF , but also in T CM and T EM , indicating that there is increased proliferation among these mature CD8 1 T cells, a finding that may reflect compensation for the increased recruitment of cells responsive to host alloantigen and subsequent activation-induced cell death. Despite the increased expression of Ki-67 in T CM and T EM , there was no increase in the absolute number of T CM and T EM in cGVHD patients compared with normal controls, suggesting that the levels of T CM and T EM in cGVHD patients, but not the number of T EFF cells, remain under homeostatic control. Two of the markers for T cell activation used in this study, HLA-DR and granzyme, gave unexpected results in tolerant patients. Neither was significantly increased in cGVHD patients, but their expression was increased in tolerant patients, suggesting that the resolution of GVHD can occur without complete normalization of CD8 1 T cell phenotype as defined by GVHD indicates graft-versus-host disease; IST, immunosuppression therapy. *Data consist of mean 6 SEM and P values. All P values represent comparisons between patients and normal controls and are adjusted for age of patients and normal controls. Adjusted P values >.05 are omitted.
†The chronic GVHD without IST patient group consisted of 12 patients with ''mild'' and 5 patients with ''moderate/severe'' disease. There was a nonsignificant trend for higher perforin expression in patients with ''moderate/severe'' compared with ''mild'' disease (52% 6 6% versus 37% 6 7%, P 5.12), but the expression of Ki-67 was similar in patients with ''mild'' and ''moderate/severe'' disease (6% 6 2% and 7% 6 3%).
‡CD95 expression was significantly greater in chronic GVHD patients during IST compared with chronic GVHD patients without IST (59% 6 3% versus 47% 6 4%, P 5 .02). §Perforin expression in patients was highest in the T EFF subset in both the RA 2 and RA + T EFF subsets of patients (50% 6 3% and 58% 6 3%), and normal controls (38% 6 6% and 51% 6 7%, respectively). ¶The highest levels of granzyme expression in tolerant patients was observed in T EM cells (43% 6 7%), and in RA 2 and RA + T EFF cells (37% 6 6% and 41% 6 6%). Among normal controls, granzyme expression in CD8 subsets was also higher in the RA 2 T EFF , RA + T EFF , and T EM cells (28% 6 7%, 30% 6 8%, and 24% 6 7%) compared with the average for all CD8 + T cells (11% 6 4%).
t
The study population for the annexin staining included 27 patients (9 with chronic GVHD without IST; 7 with chronic GVHD during IST; and 11 tolerant patients), and 12 normal controls. homeostasis in normal healthy controls. The functional significance of this observation is unknown, but it is consistent with the hypothesis that clinical tolerance in HCT recipients is induced and maintained by an active cellular mechanism.
In contrast to the expansion of CD8 1 T EFF cells in cGVHD patients, there was a reciprocal decrease in the percentages and absolute number of T N , and an increased expression of Ki-67 by T N in cGVHD patients overall, consistent with the hypothesis that ongoing alloantigenic stimulation is driving the activation, differentiation, and/or apoptosis of T N and resulting in the accumulation of T EFF cells. In a multivariate regression model, the percentages of CD8 1 T N and T EFF was found to change significantly with age in both patients and normal controls, with decreasing percentages of T N and increasing percentages of T EFF in older individuals. However, the absolute number of T N remained significantly lower in patients with cGVHD even after adjusting for the age effect. This may be because of limited thymic function after HCT, increased activation induced cell death, a deficiency of growth factors, or other changes in the lymphoid microenvironment that compromise the production and survival of T cells. These changes may be further compounded by cytolytic and inflammatory consequences of cGVHD.
The use of IST had no apparent effect on the total CD3 1 and CD8 1 T cell counts in cGVHD patients, whereas CD4 1 T cell counts were significantly decreased in cGVHD patients during IST, suggesting that CD4 1 T cells are more sensitive to IST than CD8 1 T cells in these patients. IST was also associated with a decrease in the percentage and absolute number of RA 2 T EFF and an increase in the percentage and absolute number of RA 1 T EFF , suggesting that RA 2 T EFF are relatively sensitive to IST, whereas RA 1 T EFF are relatively resistant. This effect may be explained partly by a decrease in apoptosis and Fas expression in the RA 1 T EFF subset, compared with the RA 2 T EFF subset and the overall CD8 1 T cell population (data not shown). The trend toward normalization of the percentage of T N in tolerant patients is consistent with the clinical observation that immune reconstitution after HCT is delayed in the presence of cGVHD.
CMV serostatus of the patient had a significant effect on CD8 T cell subsets in this cohort of HCT patients, consistent with what is known about the alterations in peripheral T cell homeostasis associated with latent CMV infection [15] . CMV seropositive patients in our HCT cohort had higher CD3 1 and CD8 1 T cell counts overall, but a lower percentage of T N , and a higher percentage and absolute number of CD8 1 T EFF cells, compared with seronegative patients. Peggs et al. studied T cell reconstitution during the first 6 months following autologous HCT recipients and observed increased CD8 1 T cell counts in pa-tients with active CMV infection compared with patients who remained free of CMV infection [16] . The CMV effect on CD8 1 T N and T EFF in our study paralleled the independent age effect. In a separate study, we found no statistically significant association of latent CMV infection with risk of cGVHD (Flowers et al., unpublished results).
The first differentiation markers shown to be helpful in defining T cell subsets were CD45RA and CCR7 in a study by Sallusto et al. [18] , where it was demonstrated that ''central memory'' and ''effector memory'' CD8 1 T cells could be distinguished by the expression of CD45RA 2 CCR7 1 and CD45RA 2 CCR7 2 , respectively. We chose an alternative approach to defining mature central memory and effector cells based on studies by Bachmann et al. [19] and Huster et al. [20] . Huster et al. [20] demonstrated that CD127 is a marker for memory CD8 1 T cells in the mouse, and they showed that CD127 high CD8 1 T cells had a high level of proliferation and were capable of long-term survival compared with CD127 low CD8 1 T cells. They also demonstrated that CD62L and CD127 expression following antigenic priming distinguish T CM (CD127 high CD62L high ) from T EM (CD127 high CD62L low ) CD8 1 T cells. Bachmann et al. examined changes in CD62L 1 CD127 1 T CM , CD62L 2 CD127 1 T EM , and CD62L 2 CD127 2 T EFF CD8 1 T cells after acute and chronic viral infection in mice. They showed that CD62L 2 CD127 1 T EM expand early after antigenic stimulation, and that additional stimulation leads to down-regulation of CD127 expression and a higher proportion of CD62L 2 CD127 2 T EFF , whereas cessation of stimulation leads to reexpression of CD62L and increase in the percentage of CD62L 1 CD127 1 T CM [19] . They also showed that T EFF display high levels of lytic activity and cytokine production after antigenic stimulation. T CM , however, showed high levels of IL-2 secretion and proliferation [19] . In HIV patients with advanced disease and increased viral load, Pairidini et al. [21] demonstrated that decreased CD127 expression by CD8 1 CD62L 2 cells corresponded to an activated phenotype with increased production of interferon-gamma (IFN-g) and expression of Ki-67. These findings parallel our observations of an overall decrease in CD127 expression and increase in CD62L 2 CD127 2 T EFF associated with cGVHD, whereas normalization of CD127 expression and percentage of T EFF correlates with disease resolution and the development of tolerance.
There has been little information available about CD8 1 T cell subsets in cGVHD. Yamashita et al. [9] measured CD8 1 T CM as CD45RA 2 CCR7 1 and reported a roughly 2-fold increase in the percentage of CD8 1 T CM in cGVHD patients compared with normal controls (23.3% 6 2.0% versus 11.8% 6 1.0%, P \ .0001). We defined T CM as explained above (CD45RA 2 CD62L 1 CD127 1 ) and observed no significant difference in either the percentage or absolute number of T CM in cGVHD patients compared with normal controls, with only a nonsignificant trend for lower numbers of T CM during IST. D'Asaro et al. [10] showed an increased in the percentage of CD45RA 1 CCR7 2 cells, which they termed T EMRA cells, and a decrease in percentage of CD8 1 T N cells in a study of 12 patients with cGVHD, all of which were on IST at the time of study. We also observed an increase in a CD45RA 1 T EFF subset in patients with cGVHD overall, but this increase was only marginal in patients without IST compared with controls (21% 6 3% versus 12% 6 2%, P 5 .05), whereas the increase was much more significant in cGVHD patients during IST (28% 6 3.0%, P \ .001), suggesting that use of IST leads to an expansion rather than a reduction of this RA 1 T EFF subset. The RA 2 T EFF population, however, is shown to be more significantly increased in patients with GVHD without IST and, in contrast to the RA 1 T EFF population, is decreased to normal levels in patients during IST. CD45RA 1 T EFF have been described as cells approaching ''endstage differentiation'' by some investigators, including Almanzar et al. [22] in a study of CMV immunity. CD45RA 1 T EFF are not a uniform population but variably express granzyme B, tumor necrosis factor-alpha (TNF-a), IFN-g, and FasL [23] . Carrasco et al. [24] studied clonal human effector T cell responses ex vivo in a melanoma model and demonstrated that CD45RA 1 CCR7 2 MAGE-3 specific cytotoxic T cells (CTL) could proliferate after rechallenge with antigen. These cells subsequently lose expression of CD45RA and temporarily express CCR7. Expression of CD45RA recovered, and CCR7 expression was lost again, at 10 to 15 days following antigen stimulation. These investigators concluded that CD45RA expression is not a marker of terminal differentiation in memory CD8 1 T cells, but rather that CD45RA 1 CCR7 2 CD8 1 T cells are ''transitional'' or ''stable resting'' effector T cells. Assuming that CD45RA expression by CD62L 2 CD127 2 CD8 1 T cells in cGVHD patients is analogous to the ex vivo tumor model of Carrasco et al. [24] , we would infer that RA 2 T EFF have recently encountered and responded to host alloantigen, whereas RA 1 T EFF have not. The concept that RA 2 T EFF are activated while RA 1 T EFF are quiescent is consistent with the observation that the percentage of RA 2 T EFF is reduced in cGVHD patients during IST indicating the effectiveness of IST in blocking activation of CD8 1 T EFF , whereas the relative number of quiescent RA 1 T EFF is increased in patients receiving IST.
Clonal deletion and T cell exhaustion have previously been implicated in the development of tolerance. Programmed Death 1 (PD-1) is a cell-surface receptor that has been shown to be involved in the negative regulation of CD8 1 T cells and has been implicated in the development of T cell anergy or nonresponsiveness in animal models of chronic infection. Several recent clinical studies have shown an up-regulation of PD-1 associated with T cell exhaustion of CD8 1 T cells in patients chronically infected with HIV and HCV [25] [26] [27] [28] . We observed no significant difference in PD-1 expression in patients with cGVHD or in tolerant patients compared with healthy controls, suggesting that PD-1 probably does not mediate the development of nonresponsiveness to host alloantigen in HCT recipients. Evidence for clonal deletion by activation induced cell death, however, is supported by the evidence showing increased expression of Ki-67 and increased apoptosis in patients with cGVHD compared with tolerant patients and normal controls.
In summary, the results reported here support the hypothesis that there is a sustained activation and expansion of CD8 1 T cells in patients with cGVHD. The relevant findings include an overall decrease in CD127 expression, an expansion in the percentage and absolute number of CD8 1 T EFF cells, and an increase in perforin, Ki-67, and annexin expression in patients with cGVHD. The increase in effector T cells was most prominent in older patients and patients who were CMV seropositive before transplantation. The increase in T EFF cells was accompanied by a reciprocal decrease in T N , whereas the absolute number of T CM and T EM remained within the normal range both in cGVHD and tolerant patients. Perforin, Ki-67, and annexin levels in CD8 1 T cells normalize in tolerant patients, but HLA-DR and granzyme A expression are increased in tolerant patients. PD-1 expression was within the normal range in both cGVHD and tolerant patients. IST use was shown to result in a decrease in the relative and absolute number of CD8 1 T cells that were RA 2 T EFF , and an increase in RA 1 T EFF cells. Overall, these results are consistent with the hypothesis that CD8 1 T cells play a role in mediating the immunopathology of cGVHD, and they furthermore suggest that tolerance after HCT does not necessarily correlate with a normalization of the CD8 1 T cell phenotype. Although our study was limited to a cross-sectional analysis of cGVHD and tolerant patients, the evidence provided are sufficiently compelling to prompt future longitudinal studies that more thoroughly explore differences in signaling, intracellular pathways, and effector functions of CD8 1 T cells in these patients.
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